GeneDx Holdings (WGS) Non-Current Deffered Revenue (2020 - 2021)
GeneDx Holdings (WGS) posted quarterly Non-Current Deffered Revenue of $295.0 million for Q2 2021, down 0.64% quarter-over-quarter from $297.0 million in Q1 2021.
GeneDx Holdings (WGS) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
GeneDx Holdings (WGS) has reported Non-Current Deffered Revenue for 2 consecutive years, with $295.0 million the latest figure, recorded in Q2 2021.
- In Q2 2021, Non-Current Deffered Revenue changed N/A year-over-year to $295.0 million; the TTM figure through Jun 2021 stood at $295.0 million (changed N/A YoY), while the FY2020 annual figure was $132.0 million, changed N/A from the prior year.
- Non-Current Deffered Revenue declined to $295.0 million in Q2 2021 per WGS's latest filing, from $297.0 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $297.0 million in Q1 2021 and bottomed at $15.5 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | - |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | - |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 32.59 Mn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | - |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | - |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 17.00 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | - |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | - |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | - |
| 10 | GeneDx Holdings | 2.08 Bn | 1.94 Bn | 78.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 295.05 Mn |
| Mar 31, 2021 | 296.95 Mn |
| Dec 31, 2020 | 131.99 Mn |
| Sep 30, 2020 | 15.50 Mn |